National Health (Weighted average disclosed price – first transitional disclosure cycle) Determination 2011 (No. PB 81 of 2011)
7Adjusted approved ex-manufacturer price for brands of pharmaceutical items – unadjusted price reduction is at least 10%
Start here
Get a plain-English read of 7
Turn the raw legal text into a practical explanation grounded in National Health (Weighted average disclosed price – first transitional disclosure cycle) Determination 2011 (No. PB 81 of 2011).
7 Adjusted approved ex-manufacturer price for brands of pharmaceutical items – unadjusted price reduction is at least 10%
For paragraph 99ADB(4) of the Act, the adjusted approved ex-manufacturer price for a brand of pharmaceutical item specified in column 2 of Schedule 1 is an amount equal to the amount of the weighted average disclosed price of that brand of pharmaceutical item determined under section 5 of this instrument.